Table 3 Overall and post-relapse EFS in ALL patients by DPβ1 pocket 1–4 molecular signature
Amino-acid signature | DP supertype | Overall EFS | Post-relapse EFS | ||||||
|---|---|---|---|---|---|---|---|---|---|
No. of events/no. patients | % (se) at 5 years | % (se) at 10 years | P-value (log-rank test) | No. of events/no. of patients | % (se) at 5 years | % (se) at 10 years | P-value (log-rank test) | ||
Asp84-Lys69 | DP 1, 3 | 111/248 | 58.8 (3.1) | 55.2 (3.2) | 0.007 | 62/102 | 39.2 (4.8) | 39.2 (4.8) | 0.2 |
Non-Asp84-Lys69 | DP 2, 4, 6, 8, 11, 15 | 198/550 | 67.3 (2.0) | 64.5 (2.0) | 104/192 | 49.6 (3.6) | 44.0 (3.8) | ||
Gly84-Glu69 | DP 2 | 57/161 | 68.9 (3.6) | 65.1 (3.8) | 0.3 | 28/56 | 53.3 (6.7) | 48.4 (6.9) | 0.2 |
Non-Gly84-Glu69 | DP 1, 3, 4, 6, 8, 11, 15 | 252/637 | 63.6 (1.9) | 60.7 (1.9) | 138/238 | 44.2 (3.2) | 40.7 (3.3) | ||
Gly84-Lys69 | DP 4 | 252/655 | 65.0 (1.9) | 61.9 (1.9) | 0.6 | 133/242 | 48.0 (3.2) | 43.6 (3.3) | 0.2 |
Non-Gly84-Lys69 | DP 1, 2, 3, 6, 8, 11, 15 | 57/143 | 62.9 (4.0) | 60.0 (4.1) | 33/52 | 36.3 (6.7) | 36.3 (6.7) | ||
Asp84-Glu69 | DP 6, 8 | 45/117 | 62.4 (4.5) | 61.4 (4.5) | 1.0 | 27/42 | 40.3 (7.6) | 35.3 (7.4) | 0.3 |
Non-Asp84-Glu69 | DP 1, 2, 3, 4, 11, 15 | 264/681 | 65.0 (1.8) | 61.6 (1.9) | 139/252 | 46.9 (3.2) | 43.5 (3.3) | ||
Asp84-Arg69 | DP 11 | 11/34 | 67.6 (8.0) | 67.6 (8.0) | 0.6 | 5/10 | 50.0 (15.8) | 50.0 (15.8) | 0.7 |
Non-Asp84-Arg69 | DP 1, 2, 3, 4, 6, 8, 15 | 298/764 | 64.5 (1.7) | 61.3 (1.8) | 161/284 | 45.8 (3.0) | 42.0 (3.1) | ||
Val84-Arg69 | DP 15 | 5/12 | 58.3 (14.2) | 58.3 (14.2) | 0.9 | 3/5 | 40.0 (21.9) | 40.0 (21.9) | 0.9 |
Non-Val84-Arg69 | DP 1, 2, 3, 4, 6, 8, 11 | 304/786 | 64.7 (1.7) | 61.6 (1.8) | 163/289 | 46.1 (2.9) | 42.3 (3.0) | ||
